Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Accumulated Expenses: 2013-2020

Historic Accumulated Expenses for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $3.4 million.

  • Larimar Therapeutics' Accumulated Expenses fell 6.49% to $3.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $3.4 million, marking a year-over-year decrease of 6.49%. This contributed to the annual value of $2.3 million for FY2019, which is 46.98% down from last year.
  • Per Larimar Therapeutics' latest filing, its Accumulated Expenses stood at $3.4 million for Q3 2020, which was down 10.85% from $3.8 million recorded in Q2 2020.
  • Larimar Therapeutics' 5-year Accumulated Expenses high stood at $6.7 million for Q1 2016, and its period low was $981,000 during Q1 2020.
  • Over the past 3 years, Larimar Therapeutics' median Accumulated Expenses value was $3.6 million (recorded in 2019), while the average stood at $3.5 million.
  • Per our database at Business Quant, Larimar Therapeutics' Accumulated Expenses soared by 67.06% in 2016 and then crashed by 70.26% in 2020.
  • Over the past 5 years, Larimar Therapeutics' Accumulated Expenses (Quarterly) stood at $3.7 million in 2016, then grew by 14.47% to $4.3 million in 2017, then dropped by 0.28% to $4.3 million in 2018, then plummeted by 46.98% to $2.3 million in 2019, then decreased by 6.49% to $3.4 million in 2020.
  • Its last three reported values are $3.4 million in Q3 2020, $3.8 million for Q2 2020, and $981,000 during Q1 2020.